| Name | Title | Contact Details |
|---|---|---|
Dan Kuykendall |
Chief Technology Officer | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Perceptual Systems, LLC, was founded in 2009, and is a Woman Owned Small Business (WOSB). Our focus is on providing innovative, quality, cost-effective solutions to a wide range of Information Technology challenges in both Public and Private Sector organizations.
Vignette is a Hamilton, VA-based company in the Software and Internet sector.
See how fast, easy, and accurate we are. Offering automated genotyping services that improve the quality of your research. Click for real-time PCR results!
Protect your network by eliminating lateral movement in real time and in an autonomous way to avoid any damage to your critical assets and systems.